Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Diasorin SpACHIX:DIAM -1.71%78 EV-to-OCF is 12.17 as of Jul. 14, 2026, which is 38% below its 10-year median of 19.73. GuruFocus rates CHIX:DIAM with a GF Score™ of 78/100 and a GF Value™ of €90.24 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, Diasorin SpA ranks worse than 63.85% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Diasorin SpA's Enterprise Value is €4,013 Mil.
Diasorin SpA's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was €330 Mil. Therefore, Diasorin SpA's EV-to-OCF for today is 12.17.
The historical rank and industry rank for Diasorin SpA's EV-to-OCF or its related term are showing as below:
CHIX:DIAm'
s EV-to-OCF Range Over the Past 10 Years
Min: 11.21 Med: 19.73 Max: 50.88
Current: 12.17
During the past 13 years, the highest EV-to-OCF of Diasorin SpA was 50.88. The lowest was 11.21. And the median was 19.73.
CHIX:DIAm's EV-to-OCF is ranked worse than 63.85% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: 6.22
vs CHIX:DIAm: 12.17
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Diasorin SpA's PE Ratio (TTM) for today is calculated as:
Diasorin SpA's share price for today is €69.54.
Diasorin SpA's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.642.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Diasorin SpA EV-to-OCF Related Terms
Diasorin SpA EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Diasorin SpA's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Diasorin SpA's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diasorin SpA EV-to-OCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Diasorin SpA's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Diasorin SpA's EV-to-OCF falls into.
Diasorin SpA's current Enterprise Value is €4,013 Mil.
Diasorin SpA's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €330 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diasorin SpA (CHIX:DIAM) has a EV-to-OCF of 12.17 as of Jul. 14, 2026. This is 38% below median its historical median of 19.73. Over the past decade, Diasorin SpA's EV-to-OCF has ranged from 11.21 to 50.88. According to the industry distribution chart, Diasorin SpA ranks #136 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 63.8%.
Is Diasorin SpA's EV-to-OCF too high?
Diasorin SpA's current EV-to-OCF of 12.17 is 38% below median its 10-year median of 19.73. Over the past 10 years, this metric has ranged from a low of 11.21 to a high of 50.88. The Medical Diagnostics & Research industry median EV-to-OCF is 6.22. Diasorin SpA's value of 12.17 is 95.7% above this industry median. Based on the distribution chart, Diasorin SpA ranks #136 out of 213 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Diasorin SpA has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Diasorin SpA's EV-to-OCF compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Diasorin SpA ranks #136 out of 213 companies for EV-to-OCF. This places Diasorin SpA in the lower half of its industry. The industry median EV-to-OCF is 6.22. Diasorin SpA's value of 12.17 is 95.7% above this benchmark. Historically, Diasorin SpA's own EV-to-OCF has ranged from 11.21 to 50.88 over the past decade. While the company's 10-year median is 19.73 vs. the industry median of 6.22, Diasorin SpA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Diagnostics & Research company?
The median EV-to-OCF among Medical Diagnostics & Research companies is 6.22, based on 213 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Diasorin SpA's current EV-to-OCF of 12.17 is 95.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median EV-to-OCF is 6.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diasorin SpA's current EV-to-OCF is 12.17, which is 38% below median its own 10-year median of 19.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diasorin SpA stock overvalued right now?
Based on GuruFocus' analysis, Diasorin SpA (CHIX:DIAM) is currently considered Modestly Undervalued. The stock's GF Value™ is €90.24, compared to a current price of €69.54 — trading 22.9% below its estimated fair value. The current EV-to-OCF is 12.17, which is 38% below median its 10-year median of 19.73 and 95.7% above the Medical Diagnostics & Research industry median of 6.22. Diasorin SpA's overall GF Score™ is 78/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Diasorin SpA (CHIX:DIAM), the current EV-to-OCF is 12.17 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diasorin SpA (CHIX:DIAM) Overvalued in 2026?
Based on GuruFocus' analysis, Diasorin SpA stock appears to be undervalued.
The current stock price of €69.54 is trading 22.9% below its estimated GF Value™ of €90.24.
GuruFocus considers Diasorin SpA to be Modestly Undervalued.
Key valuation signals for CHIX:DIAM:
EV-to-OCF: 12.17 (38% below median its 10-year median of 19.73)
GF Value™: €90.24 vs. price of €69.54 (22.9% below fair value)
Industry Position: 95.7% above the Medical Diagnostics & Research median (#136 of 213)
No single metric tells the full story. See the CHIX:DIAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diasorin develops and manufactures a broad portfolio of in vitro diagnostics for detecting pathogens and sample contamination from the human body, as well as for use in industrial settings, such as food and water contamination testing. The company operates three segments: immunodiagnostics (69% of sales), molecular diagnostics (16%), and licensed technologies (14%). Diasorin was an important manufacturer of covid tests, which boosted its profits during the pandemic, but this segment's importance has decreased over the years, and in 2025, it accounted for only 1% of total sales.
78GF Score
Get the complete analysis for CHIX:DIAM
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:DIAM has been successfully added to your 
